Design, Synthesis, and Evaluation of Potent and Selective Ligands for the Dopamine 3 (D3) Receptor with a Novel in Vivo Behavioral Profile

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2008 Sep 13

PMID 18785726

Citations 16

Authors

Jianyong Chen

Gregory T Collins

Jian Zhang

Chao-Yie Yang

Beth Levant

James Woods

Shaomeng Wang

Affiliations

Soon will be listed here.

Abstract

A series of compounds structurally related to pramipexole were designed, synthesized, and evaluated as ligands for the dopamine 3 (D3) receptor. Compound 12 has a K(i) value of 0.41 nM to D3 and a selectivity of >30000- and 800-fold over the D1-like and D2 receptors, respectively. Our in vivo functional assays showed that this compound is a partial agonist at the D3 receptor with no detectable activity at the D2 receptor.

Citing Articles

Developing Photoaffinity Probes for Dopamine Receptor D to Determine Targets of Parkinson's Disease Drugs.

Kim S, Doukmak E, Flax R, Gray D, Zirimu V, de Jong E ACS Chem Neurosci. 2022; 13(20):3008-3022.

PMID: 36183275 PMC: 9585581. DOI: 10.1021/acschemneuro.2c00544.

Approach to the specificity and selectivity between D2 and D3 receptors by mutagenesis and binding experiments part I: Expression and characterization of D2 and D3 receptor mutants.

Legros C, Rojas A, Dupre C, Brasseur C, Riest-Fery I, Muller O Protein Sci. 2022; 31(12):e4459.

PMID: 36177735 PMC: 9667827. DOI: 10.1002/pro.4459.

Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators.

Morales P, Muller C, Jagerovic N, Reggio P Front Mol Biosci. 2022; 9:841190.

PMID: 35281260 PMC: 8914543. DOI: 10.3389/fmolb.2022.841190.

The Significance of Chirality in Drug Design and Synthesis of Bitopic Ligands as D Receptor (DR) Selective Agonists.

Battiti F, Cemaj S, Guerrero A, Shaik A, Lam J, Rais R J Med Chem. 2019; 62(13):6287-6314.

PMID: 31257877 PMC: 8272914. DOI: 10.1021/acs.jmedchem.9b00702.

In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Lemos A, Melo R, Preto A, Almeida J, Moreira I, Cordeiro M Curr Neuropharmacol. 2018; 16(6):786-848.

PMID: 29521236 PMC: 6080095. DOI: 10.2174/1570159X16666180308161642.

References

Koob G, Caine S . Cocaine addiction therapy--are we partially there?. Nat Med. 1999; 5(9):993-5. DOI: 10.1038/12429. View

Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F . Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem. 2003; 46(18):3822-39. DOI: 10.1021/jm0211220. View

Ding K, Chen J, Ji M, Wu X, Varady J, Yang C . Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands. J Med Chem. 2005; 48(9):3171-81. DOI: 10.1021/jm049031l. View

Wustrow D, Belliotti T, Glase S, Kesten S, Johnson D, Colbry N . Aminopyrimidines with high affinity for both serotonin and dopamine receptors. J Med Chem. 1998; 41(5):760-71. DOI: 10.1021/jm9707378. View

Rasmussen S, Choi H, Rosenbaum D, Kobilka T, Thian F, Edwards P . Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature. 2007; 450(7168):383-7. DOI: 10.1038/nature06325. View

Joyce J . Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther. 2001; 90(2-3):231-59. DOI: 10.1016/s0163-7258(01)00139-5. View

Robarge M, Husbands S, Kieltyka A, Brodbeck R, Thurkauf A, Newman A . Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype. J Med Chem. 2001; 44(19):3175-86. DOI: 10.1021/jm010146o. View

Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B . Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology. 1999; 52(5):938-43. DOI: 10.1212/wnl.52.5.938. View

Bancroft G, Morgan K, Flietstra R, Levant B . Binding of [3H]PD 128907, a putatively selective ligand for the D3 dopamine receptor, in rat brain: a receptor binding and quantitative autoradiographic study. Neuropsychopharmacology. 1998; 18(4):305-16. DOI: 10.1016/S0893-133X(97)00162-0. View

10.

Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V . Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. J Med Chem. 2003; 47(1):143-57. DOI: 10.1021/jm0309811. View

11.

Levant B . The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev. 1997; 49(3):231-52. View

12.

Levant B, Grigoriadis D, Desouza E . Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. J Pharmacol Exp Ther. 1992; 262(3):929-35. View

13.

Collins G, Witkin J, Newman A, Svensson K, Grundt P, Cao J . Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther. 2005; 314(1):310-9. PMC: 1201434. DOI: 10.1124/jpet.105.085472. View

14.

Newman A, Grundt P, Nader M . Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem. 2005; 48(11):3663-79. DOI: 10.1021/jm040190e. View

15.

Collins G, Newman A, Grundt P, Rice K, Husbands S, Chauvignac C . Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl). 2007; 193(2):159-70. PMC: 3094913. DOI: 10.1007/s00213-007-0766-3. View

16.

Bettinetti L, Schlotter K, Hubner H, Gmeiner P . Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. J Med Chem. 2002; 45(21):4594-7. DOI: 10.1021/jm025558r. View

17.

Cleek K, Dinh D, Duncan J, Haber C, Huff R, Lajiness M . Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans. J Med Chem. 2001; 44(26):4716-32. DOI: 10.1021/jm010145w. View

18.

Wustrow D, Wise L, Cody D, MacKenzie R, Georgic L, Pugsley T . Studies of the active conformation of a novel series of benzamide dopamine D2 agonists. J Med Chem. 1994; 37(24):4251-7. DOI: 10.1021/jm00050a022. View

19.

Grundt P, Carlson E, Cao J, Bennett C, McElveen E, Taylor M . Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem. 2005; 48(3):839-48. DOI: 10.1021/jm049465g. View

20.

Millan M, Maiofiss L, Cussac D, Audinot V, Boutin J, Newman-Tancredi A . Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002; 303(2):791-804. DOI: 10.1124/jpet.102.039867. View